EUCTR2006-005928-16-CZ进行中（未招募）不适用
An open, randomised, parallel group, multicentre study to compare the efficacyand safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects withmild to moderate persistent, reversible asthma.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects between 4-12 years of age. Female subjects must be pre-menarche to be eligible.
- •2. Known history of mild to moderate persistent asthma for at least 6 months prior to the screening visit. Subjects with mild asthma must, in the investigator’s opinion, require the use of a long acting beta2-agonist.
- •3. Demonstrate a FEV1 of 60% to 100% of predicted normal values (Zapletal et al., 1977) during the screening phase following appropriate withholding of asthma medications (if applicable).
- •- No beta2-agonist use on day of screening.
- •- No use of inhaled combination asthma therapy on day of screening.
- •- Inhaled corticosteroids are allowed on day of screening.
- •4. Documented reversibility of at least 15% in FEV1 during the screening phase.
- •5. Demonstrate satisfactory technique in the use of the pressurised Metered Dose Inhaler (pMDI) and spacer device.
- •6. Willing and able to enter information in the electronic diary (parental help is acceptable) and attend all study visits.
- •7. Willing and able to substitute study medication for their pre study prescribed asthma medication for the duration of the study.
- •8. Written informed consent obtained from the parent(s)/ legal representative, and where possible informed assent from the subject (for a definition of legal representative” see national laws).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Near fatal or life-threatening (including intubation) asthma within the past year.
- •2. Hospitalisation or an emergency visit due to asthma in the 4 weeks before the Screening Visit.
- •3. History of systemic (injectable) corticosteroid medication within 1 month before the Screening Visit.
- •4. History of leukotriene receptor antagonist use, e.g. montelukast, within the past week.
- •5. Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, or cardiac dysrhythmia. ‘Clinically significant’ is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study.
- •6. In the investigator’s opinion, a clinically relevant upper or lower respiratory infection within 4 weeks prior to the Screening Visit.
- •7. Significant, non-reversible, active pulmonary disease (e.g., chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).
- •8. Known Human Immunodeficiency Virus (HIV)-positive status.
- •9. Current smoking history within 12 months prior to the Screening Visit.
- •10. Current evidence or history of alcohol and/or substance abuse within 12 months prior to the Screening Visit.
- •11. Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within the past week.
- •12. Current use of medications that will have an effect on bronchospasm and/or pulmonary function.
- •13. Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications or components.
- •14. Receipt of an investigational drug within 30 days of the Screening Visit (12 weeks if an oral or injectable steroid).
- •15. Current participation in a clinical study.
研究者
相似试验
进行中（未招募）
不适用
An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiFormTM pMDI compared with Fluticasone pMDI plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma. - FLAIR studieAsthma bronchial.MedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2007-001634-13-BEMundipharma Research Ltd.200
进行中（未招募）
不适用
An open, randomised, parallel group, multicentre study to compare the efficacyand safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects withmild to moderate persistent, reversible asthma.Asthma bronchialMedDRA version: 8.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2006-005928-16-DEMundipharma Research Ltd.200
进行中（未招募）
不适用
An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiFormTM pMDI vs Fluticasone pMDI plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma.Asthma bronchial.MedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2007-001634-13-DEMundipharma Research Limited200
进行中（未招募）
不适用
An open, randomised, parallel group, multicentre study to compare the efficacyand safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects withmild to moderate persistent, reversible asthma.Asthma bronchialMedDRA version: 8.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2006-005928-16-HUMundipharma Research Ltd.200
进行中（未招募）
1 期
An open, randomised, parallel group, multicentre study to compare the efficacyand safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects withmild to moderate persistent, reversible asthma.EUCTR2006-005928-16-FRMundipharma Research Ltd.